Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

A Study of RO5185426 in Patients With Metastatic Melanoma
A SINGLE ARM, OPEN LABEL, EXPANDED ACCESS STUDY OF RG7204 IN PREVIOUSLY TREATED PATIENTS WITH METASTATIC MELANOMA
Status: Enrolling
Updated:  3/17/2016
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of RO5185426 in Patients With Metastatic Melanoma
A SINGLE ARM, OPEN LABEL, EXPANDED ACCESS STUDY OF RG7204 IN PREVIOUSLY TREATED PATIENTS WITH METASTATIC MELANOMA
Status: Enrolling
Updated: 3/17/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of RO5185426 in Patients With Metastatic Melanoma
A SINGLE ARM, OPEN LABEL, EXPANDED ACCESS STUDY OF RG7204 IN PREVIOUSLY TREATED PATIENTS WITH METASTATIC MELANOMA
Status: Enrolling
Updated:  3/17/2016
Clinical Research Facility
mi
from
Columbia, SC
A Study of RO5185426 in Patients With Metastatic Melanoma
A SINGLE ARM, OPEN LABEL, EXPANDED ACCESS STUDY OF RG7204 IN PREVIOUSLY TREATED PATIENTS WITH METASTATIC MELANOMA
Status: Enrolling
Updated: 3/17/2016
Clinical Research Facility
mi
from
Columbia, SC
Click here to add this to my saved trials
A Study of RO5185426 in Patients With Metastatic Melanoma
A SINGLE ARM, OPEN LABEL, EXPANDED ACCESS STUDY OF RG7204 IN PREVIOUSLY TREATED PATIENTS WITH METASTATIC MELANOMA
Status: Enrolling
Updated:  3/17/2016
Clinical Research Facility
mi
from
Nashville, TN
A Study of RO5185426 in Patients With Metastatic Melanoma
A SINGLE ARM, OPEN LABEL, EXPANDED ACCESS STUDY OF RG7204 IN PREVIOUSLY TREATED PATIENTS WITH METASTATIC MELANOMA
Status: Enrolling
Updated: 3/17/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of RO5185426 in Patients With Metastatic Melanoma
A SINGLE ARM, OPEN LABEL, EXPANDED ACCESS STUDY OF RG7204 IN PREVIOUSLY TREATED PATIENTS WITH METASTATIC MELANOMA
Status: Enrolling
Updated:  3/17/2016
Clinical Research Facility
mi
from
Dallas, TX
A Study of RO5185426 in Patients With Metastatic Melanoma
A SINGLE ARM, OPEN LABEL, EXPANDED ACCESS STUDY OF RG7204 IN PREVIOUSLY TREATED PATIENTS WITH METASTATIC MELANOMA
Status: Enrolling
Updated: 3/17/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of RO5185426 in Patients With Metastatic Melanoma
A SINGLE ARM, OPEN LABEL, EXPANDED ACCESS STUDY OF RG7204 IN PREVIOUSLY TREATED PATIENTS WITH METASTATIC MELANOMA
Status: Enrolling
Updated:  3/17/2016
Clinical Research Facility
mi
from
Richmond, VA
A Study of RO5185426 in Patients With Metastatic Melanoma
A SINGLE ARM, OPEN LABEL, EXPANDED ACCESS STUDY OF RG7204 IN PREVIOUSLY TREATED PATIENTS WITH METASTATIC MELANOMA
Status: Enrolling
Updated: 3/17/2016
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study of RO5185426 in Patients With Metastatic Melanoma
A SINGLE ARM, OPEN LABEL, EXPANDED ACCESS STUDY OF RG7204 IN PREVIOUSLY TREATED PATIENTS WITH METASTATIC MELANOMA
Status: Enrolling
Updated:  3/17/2016
Clinical Research Facility
mi
from
Seattle, WA
A Study of RO5185426 in Patients With Metastatic Melanoma
A SINGLE ARM, OPEN LABEL, EXPANDED ACCESS STUDY OF RG7204 IN PREVIOUSLY TREATED PATIENTS WITH METASTATIC MELANOMA
Status: Enrolling
Updated: 3/17/2016
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
Systemic Therapy of Metastatic Melanoma With Multidrug Regimen Including Interferon, Interleukin-2 and BRAF Inhibitor
Status: Enrolling
Updated:  3/17/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
Systemic Therapy of Metastatic Melanoma With Multidrug Regimen Including Interferon, Interleukin-2 and BRAF Inhibitor
Status: Enrolling
Updated: 3/17/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma
COMBAT 1: A Phase II Trial of Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma
Status: Enrolling
Updated:  3/20/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma
COMBAT 1: A Phase II Trial of Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma
Status: Enrolling
Updated: 3/20/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma
COMBAT 1: A Phase II Trial of Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma
Status: Enrolling
Updated:  3/20/2016
Massachusetts General Hospital
mi
from
Boston, MA
Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma
COMBAT 1: A Phase II Trial of Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma
Status: Enrolling
Updated: 3/20/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Ensuring Communication in Hospice by Oncology Study (ECHO)
Ensuring Communication in Hospice by Oncology Study (ECHO)
Status: Enrolling
Updated:  3/21/2016
Massachusetts General Hospital
mi
from
Boston, MA
Ensuring Communication in Hospice by Oncology Study (ECHO)
Ensuring Communication in Hospice by Oncology Study (ECHO)
Status: Enrolling
Updated: 3/21/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma
A Phase Ib Study of Yervoy With Sylatron for Patients With Unresectable Stages IIIB/C/IV Melanoma
Status: Enrolling
Updated:  3/25/2016
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma
A Phase Ib Study of Yervoy With Sylatron for Patients With Unresectable Stages IIIB/C/IV Melanoma
Status: Enrolling
Updated: 3/25/2016
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma
Phase II Trial of the Effects of Interferon Alfa-2b on the Immunogenicity of a Polyvalent Melanoma Antigen Vaccine in Patients With Stage III Malignant Melanoma
Status: Enrolling
Updated:  3/30/2016
Kaplan Cancer Center
mi
from
New York, NY
Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma
Phase II Trial of the Effects of Interferon Alfa-2b on the Immunogenicity of a Polyvalent Melanoma Antigen Vaccine in Patients With Stage III Malignant Melanoma
Status: Enrolling
Updated: 3/30/2016
Kaplan Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of PI-88 in Patients With Advanced Melanoma
A Phase I/II Study of PI-88 in Advanced Malignancies (Phase I), and in Advanced Melanoma (Phase II)
Status: Enrolling
Updated:  3/30/2016
University of Colorado Health Sciences Ctr.
mi
from
Aurora, CO
Study of PI-88 in Patients With Advanced Melanoma
A Phase I/II Study of PI-88 in Advanced Malignancies (Phase I), and in Advanced Melanoma (Phase II)
Status: Enrolling
Updated: 3/30/2016
University of Colorado Health Sciences Ctr.
mi
from
Aurora, CO
Click here to add this to my saved trials
Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
A Phase II Study of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  3/30/2016
Arizona Cancer Centre
mi
from
Tuscon, AZ
Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
A Phase II Study of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 3/30/2016
Arizona Cancer Centre
mi
from
Tuscon, AZ
Click here to add this to my saved trials
Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
A Phase II Study of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  3/30/2016
University of Colorado Health Science Centre
mi
from
Denver, CO
Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
A Phase II Study of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 3/30/2016
University of Colorado Health Science Centre
mi
from
Denver, CO
Click here to add this to my saved trials
Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
A Phase II Study of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  3/30/2016
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
A Phase II Study of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 3/30/2016
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
A Phase II Study of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  3/30/2016
Sydney Cancer Centre, Royal Prince Alfred Hospital
mi
from
Camperdown,
Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
A Phase II Study of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 3/30/2016
Sydney Cancer Centre, Royal Prince Alfred Hospital
mi
from
Camperdown,
Click here to add this to my saved trials
MLN8237 and Pazopanib in Combination for Solid Tumors
Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors
Status: Enrolling
Updated:  4/1/2016
University of Illinois Cancer Center
mi
from
Chicago, IL
MLN8237 and Pazopanib in Combination for Solid Tumors
Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors
Status: Enrolling
Updated: 4/1/2016
University of Illinois Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Aurora, CO
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Boston, MA
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Rochester, MN
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Dallas, TX
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Seattle, WA
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Los Angeles, CA
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Tampa, FL
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Detroit, MI
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Saint Louis, MO
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Las Vegas, NV
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Charlotte, NC
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Status: Enrolling
Updated:  4/2/2016
mi
from
Wentworthville,
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Status: Enrolling
Updated: 4/2/2016
mi
from
Wentworthville,
Click here to add this to my saved trials
A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies
A Phase I, Open-Label, Multicenter, 3- Period, Fixed-Sequence Study to Investigate the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Detroit, MI
A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies
A Phase I, Open-Label, Multicenter, 3- Period, Fixed-Sequence Study to Investigate the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies
A Phase I, Open-Label, Multicenter, 3- Period, Fixed-Sequence Study to Investigate the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Durham, NC
A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies
A Phase I, Open-Label, Multicenter, 3- Period, Fixed-Sequence Study to Investigate the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies
A Phase I, Open-Label, Multicenter, 3- Period, Fixed-Sequence Study to Investigate the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Pleasant Hill, CA
A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies
A Phase I, Open-Label, Multicenter, 3- Period, Fixed-Sequence Study to Investigate the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Pleasant Hill, CA
Click here to add this to my saved trials
A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies
A Phase I, Open-Label, Multicenter, 3- Period, Fixed-Sequence Study to Investigate the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
Status: Enrolling
Updated:  4/2/2016
mi
from
Rio de Janeiro,
A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies
A Phase I, Open-Label, Multicenter, 3- Period, Fixed-Sequence Study to Investigate the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
Status: Enrolling
Updated: 4/2/2016
mi
from
Rio de Janeiro,
Click here to add this to my saved trials
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Status: Enrolling
Updated:  4/4/2016
Harriet Kluger
mi
from
New Haven, CT
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Status: Enrolling
Updated: 4/4/2016
Harriet Kluger
mi
from
New Haven, CT
Click here to add this to my saved trials
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Status: Enrolling
Updated:  4/4/2016
Mohammed Milhem, MD
mi
from
Iowa City, IA
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Status: Enrolling
Updated: 4/4/2016
Mohammed Milhem, MD
mi
from
Iowa City, IA
Click here to add this to my saved trials
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Status: Enrolling
Updated:  4/4/2016
Anna Pavlick, MD
mi
from
New York, NY
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Status: Enrolling
Updated: 4/4/2016
Anna Pavlick, MD
mi
from
New York, NY
Click here to add this to my saved trials
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Status: Enrolling
Updated:  4/4/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Status: Enrolling
Updated: 4/4/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Status: Enrolling
Updated:  4/4/2016
Ravi Amaravadi, MD
mi
from
Philadelphia, PA
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Status: Enrolling
Updated: 4/4/2016
Ravi Amaravadi, MD
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Status: Enrolling
Updated:  4/4/2016
UPMC - Hillman Cancer Center
mi
from
Pittsburgh, PA
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Status: Enrolling
Updated: 4/4/2016
UPMC - Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
Study to Evaluate Cellular Adoptive Immunotherapy Using Polyclonal Autologous CD8+ Antigen-Specific T Cells for Metastatic Merkel Cell Carcinoma
Status: Enrolling
Updated:  4/5/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
Study to Evaluate Cellular Adoptive Immunotherapy Using Polyclonal Autologous CD8+ Antigen-Specific T Cells for Metastatic Merkel Cell Carcinoma
Status: Enrolling
Updated: 4/5/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC
A Phase I Dose Escalation Trial: Concurrent Intensity-Modulated Radiotherapy (IMRT) and Chemotherapy With Molecular Image-Guided Adaptive Radiation Therapy (IGART) for Advanced Head and Neck Squamous Cell Carcinomas (HNSCC)
Status: Enrolling
Updated:  4/6/2016
Virginia Commonwealth University
mi
from
Richmond, VA
Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC
A Phase I Dose Escalation Trial: Concurrent Intensity-Modulated Radiotherapy (IMRT) and Chemotherapy With Molecular Image-Guided Adaptive Radiation Therapy (IGART) for Advanced Head and Neck Squamous Cell Carcinomas (HNSCC)
Status: Enrolling
Updated: 4/6/2016
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
Fairview Ridges Hospital
mi
from
Burnsville, MN
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
Fairview Ridges Hospital
mi
from
Burnsville, MN
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
Mercy Hospital
mi
from
Coon Rapids, MN
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
Mercy Hospital
mi
from
Coon Rapids, MN
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
Fairview Southdale Hospital
mi
from
Edina, MN
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
Fairview Southdale Hospital
mi
from
Edina, MN
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
Unity Hospital
mi
from
Fridley, MN
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
Unity Hospital
mi
from
Fridley, MN
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
Hutchinson Area Health Care
mi
from
Hutchinson, MN
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
Hutchinson Area Health Care
mi
from
Hutchinson, MN
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
Saint John's Hospital - Healtheast
mi
from
Maplewood, MN
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
Saint John's Hospital - Healtheast
mi
from
Maplewood, MN
Click here to add this to my saved trials